Amgen Completes Phase 3 Trial for ABP 206, Its Opdivo Biosimilar Candidate, Marking Key Milestone

Amgen Inc. (AMGN) has announced the successful completion of a Phase 3 clinical trial for ABP 206, its biosimilar candidate to Opdivo (nivolumab), a pivotal immune checkpoint inhibitor developed by Bristol Myers Squibb. The trial, which included over 1,000 patients across multiple cancer types including melanoma, non-small cell lung cancer, and renal cell carcinoma, demonstrated non-inferiority in efficacy and a comparable safety profile to the reference product. This milestone represents a critical step toward regulatory submission and potential market launch in the United States and key international markets. The completion of this trial underscores Amgen’s expanding biosimilars program and its strategic push into the oncology segment, where biosimilars are expected to generate significant cost savings and improve treatment access. With Opdivo generating approximately $8.7 billion in global sales in 2025, the entry of a biosimilar could disrupt pricing dynamics and expand patient reach, particularly in value-conscious healthcare systems. ABP 206 is designed to be interchangeable with Opdivo under FDA standards, which could lead to automatic substitution in pharmacies. The development of ABP 206 is expected to bolster Amgen’s long-term revenue potential and strengthen its position within the biotechnology sector. As a component of the iShares Biotechnology ETF (IBB) and the Health Care Select Sector SPDR Fund (XLV), Amgen’s progress may positively influence investor sentiment toward biotech equities. Analysts anticipate that if approved, ABP 206 could capture 20–25% of the Opdivo market within five years, driven by pricing advantages and physician acceptance. Investors are closely monitoring the timing of the FDA’s review, with a Biologics License Application (BLA) expected to be submitted in late 2026. The outcome could also impact competition in the broader immuno-oncology space, where biosimilars are emerging as a strategic tool for healthcare systems seeking sustainable cancer treatment models.